Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7668333 | 0.82 | MAPT (0.48) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7674963 | 0.81 | MAPT (0.45) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL6337585 | 0.81 | CNR2 (0.75) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7670851 | 0.81 | ALDH1A1 (0.46) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7676828 | 0.79 | PTGS1 (0.47) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7817127 | 0.79 | CNR2 (0.61) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7671504 | 0.79 | MAPT (0.42) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7705956 | 0.77 | LTA4H (0.72) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL7676256 | 0.77 | PTGS1 (0.45) | MAPTALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL6735126 | 0.76 | MAPT (0.40) | MAPTALDH1A1KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6797693-B2 | Methods using PTPase inhibitors and insulin | WYETH | 2004-09-28 | — | — | US | disclosed |
| US-20040167172-A1 | Combination therapy for type II diabetes or syndrome X | WYETH (US) | 2004-08-26 | — | — | US | disclosed |
| US-6734197-B2 | SYNERGIST MIXTURE OF ENZYME INHIBITOR AND SULFONYLUREA | WYETH | 2004-05-11 | — | — | US | disclosed |
| US-20030022896-A1 | PTPase inhibitors for improving cardiovascular risk profile | WYETH | 2003-01-30 | — | — | US | disclosed |
| US-20030018028-A1 | Combination therapy for type II diabetes or Syndrome X | WYETH | 2003-01-23 | — | — | US | disclosed |
| US-20030013709-A1 | Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor | WYETH (US) | 2003-01-16 | — | — | US | disclosed |
| US-20030008869-A1 | Combination of a PTPase inhibitor and a sulfonylurea agent | WYETH | 2003-01-09 | — | — | US | disclosed |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | WYETH (US) | 2002-12-26 | — | — | US | disclosed |
| US-20020198201-A1 | Combination of a PTPase inhibitor and an aldose reductase inhibitor | WYETH | 2002-12-26 | — | — | US | disclosed |
| US-20020187980-A1 | Methods using PTPase inhibitors and insulin | WYETH | 2002-12-12 | — | — | US | disclosed |
| US-6444670-B2 | ENZYME INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES; ANTI-DIABETIC AGENTS; TREATMENT OF INSULIN RESISTANCE ASSOCIATED WITH OBESITY, GLUCOSE INTOLERANCE, DIABETES MELLITUS, HYPERTENSION AND ISCHEMIC DISEASES OF VESSELS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020002187-A1 | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | WYETH | 2002-01-03 | — | — | US | disclosed |
| US-6251936-B1 | ADMINISTERING TO THE PATIENT SUFFERING FROM METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA A BENZENE OR PYRIDINE SUBSTITUTED INDOLE OR BENZOTHIOPHENE DERIVATIVES OR SALTS | AMERICAN HOME PRODUCTS CORPORATION | 2001-06-26 | — | — | US | disclosed |
| EP-1077969-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999061435-A1 | BENZOTHIOPHENES, BENZOFURANS, AND INDOLES USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020187980-A1 | Methods using PTPase inhibitors and insulin | PTPMT1, PTPA, PTPRF | MAPT 3831/4885ALDH1A1 2961/4885KMT2A 2280/4885 |
| US-20030018028-A1 | Combination therapy for type II diabetes or Syndrome X | G6PC1, PTPRS, PTPA | MAPT 4764/4885ALDH1A1 2425/4885KMT2A 1942/4885 |
| US-20020198202-A1 | Combination of a PTPase inhibitor and an antilipemic agent | PTPN6, PTPN1, PNLIP | MAPT 2402/4885ALDH1A1 2342/4885KMT2A 3508/4885 |
| US-20020002187-A1 | Benzothiophenes, benzofurans, and indoles useful in the treatment of insulin-resistance and hyperglycemia | IRS1, INSR, GPR119 | MAPT 4113/4885ALDH1A1 1497/4885KMT2A 2872/4885 |
| US-20040167172-A1 | Combination therapy for type II diabetes or syndrome X | G6PC1, PTPRS, PTPA | MAPT 4764/4885ALDH1A1 2425/4885KMT2A 1942/4885 |
| US-20030013709-A1 | Combination of a PTPase inhibitor and an alpha-glucosidase inhibitor | PTPN1, PTPRG, PTPN6 | MAPT 2515/4885ALDH1A1 2048/4885KMT2A 3731/4885 |
| US-20030008869-A1 | Combination of a PTPase inhibitor and a sulfonylurea agent | PTPRS, PTPA, PTPRCAP | MAPT 4365/4885ALDH1A1 2833/4885KMT2A 2909/4885 |
| US-20020198201-A1 | Combination of a PTPase inhibitor and an aldose reductase inhibitor | PTPMT1, LPL, PTPRE | MAPT 233/4885ALDH1A1 833/4885KMT2A 883/4885 |
| US-20030022896-A1 | PTPase inhibitors for improving cardiovascular risk profile | PTPRS, PTPRJ, PTPRF | MAPT 2424/4885ALDH1A1 3631/4885KMT2A 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.